Mergers Acquisitions

Healthcare Triangle (HCTI) unveiled a strategy to reshape its scale and capital, including acquiring Teyame.AI, a $34M revenue platform which doubles HCTI’s market cap. HCTI is marketing its QuantumNexis GenAI SaaS and exploring acquisitions like Niyama and Ezovion. A warrant inducement program lowered warrant strike prices to $2.00 and issued new warrants at $3.00. HCTI’s stock traded at $2.84 on October 13, 2025, up over 31% since September, driven by its strategic move to AI-driven patient engagement and data solutions.

Elixxer Ltd. announces the upcoming resumption of trading following the revocation of a cease trade order. Key initiatives, including a new stock option plan, received shareholder approval at the AGM. The company has also strengthened its leadership with new CEO and CFO appointments and a refreshed Board of Directors. Strategic debt restructuring and bridge financing are in place. Elixxer is actively pursuing merger and acquisition opportunities and is involved in ongoing litigation regarding its investment in Freia Farmaceutici Srl.